L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi
{"title":"Pembrolizumab对一线晚期PD-L1疗效的生物标志物？50%非小细胞肺癌癌症治疗","authors":"L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi","doi":"10.33696/cancerimmunol.3.056","DOIUrl":null,"url":null,"abstract":"Luis Cabezón-Gutiérrez Ph.D, M.D1, Sara Custodio-Cabello Ph.D, M.D1, Magda Palka-Kotlowska M.D1, Silvia María Sanchez-Luis M.D2, Parham Khosravi-Shahi Ph.D, M.D3 1Medical Oncology, Hospital Universitario de Torrejón. Universidad Francisco de Vitoria. Madrid, Spain 2Radiotherapy Oncology, Hospital Universitario de Torrejón. Madrid, Spain 3Medical Oncology, Hospital General Universitario Gregorio Marañón. Madrid, Spain *Correspondence should be addressed to Luis Cabezón-Gutiérrez; lcabezon@torrejonsalud.com","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ?50% Non-Small Cell Lung Cancer Treatment\",\"authors\":\"L. Cabezón-Gutiérrez, S. Custodio-Cabello, Magda Palka-Kotlowska, Sílvia, María Sanchez-Luis, P. Khosravi-Shahi\",\"doi\":\"10.33696/cancerimmunol.3.056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Luis Cabezón-Gutiérrez Ph.D, M.D1, Sara Custodio-Cabello Ph.D, M.D1, Magda Palka-Kotlowska M.D1, Silvia María Sanchez-Luis M.D2, Parham Khosravi-Shahi Ph.D, M.D3 1Medical Oncology, Hospital Universitario de Torrejón. Universidad Francisco de Vitoria. Madrid, Spain 2Radiotherapy Oncology, Hospital Universitario de Torrejón. Madrid, Spain 3Medical Oncology, Hospital General Universitario Gregorio Marañón. Madrid, Spain *Correspondence should be addressed to Luis Cabezón-Gutiérrez; lcabezon@torrejonsalud.com\",\"PeriodicalId\":73633,\"journal\":{\"name\":\"Journal of cancer immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/cancerimmunol.3.056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/cancerimmunol.3.056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Luis Cabezon-Gutierrez博士、M.D1、Sara Custodio-Cabello博士、M.D1、Magda Palka-Kotlowska M.D1、Silvia María Sanchez-Luis M.D2、Parham Khosravi-Shahi博士、M.D3 1医学肿瘤学、托雷洪大学医院。维多利亚弗朗西斯科大学。马德里，西班牙2托雷洪大学医院放射治疗肿瘤学。马德里，西班牙3医学肿瘤学，格雷戈里奥·马拉尼翁大学总医院。马德里，西班牙*应致函路易斯·卡贝松-古铁雷斯；lcabezon@torrejonsalud.com
Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ?50% Non-Small Cell Lung Cancer Treatment
Luis Cabezón-Gutiérrez Ph.D, M.D1, Sara Custodio-Cabello Ph.D, M.D1, Magda Palka-Kotlowska M.D1, Silvia María Sanchez-Luis M.D2, Parham Khosravi-Shahi Ph.D, M.D3 1Medical Oncology, Hospital Universitario de Torrejón. Universidad Francisco de Vitoria. Madrid, Spain 2Radiotherapy Oncology, Hospital Universitario de Torrejón. Madrid, Spain 3Medical Oncology, Hospital General Universitario Gregorio Marañón. Madrid, Spain *Correspondence should be addressed to Luis Cabezón-Gutiérrez; lcabezon@torrejonsalud.com
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
